Lapchak P A
Exp Neurol. 1993 Nov;124(1):16-20. doi: 10.1006/exnr.1993.1168.
The proposal that NGF or compounds that induce the expression of endogenous NGF may be useful in the treatment of AD is based upon a wealth of evidence showing that NGF effectively attenuates lesion-induced cholinergic deficits and cognitive impairments in animal models. In addition, a recent clinical study with chronic NGF treatment in an AD patient showed promise. Olson et al. showed that NGF treatment increased blood flow, [11C]nicotine uptake, and 11C binding in the cerebral cortex. In addition, NGF infusions normalized EEG patterns and improved performance in word recognition tests. Further clinical trials with either NGF or NGF-enhancing compounds will allow determination of whether the animal-based study approach to designing clinically relevant drugs will be advantageous to the treatment of AD. Further findings on the effectiveness of NGF in AD patients are reported by Lars Olson (this volume).
神经生长因子（NGF）或诱导内源性NGF表达的化合物可能有助于治疗阿尔茨海默病（AD），这一观点基于大量证据，这些证据表明NGF能有效减轻动物模型中损伤诱导的胆碱能缺陷和认知障碍。此外，最近一项针对AD患者的慢性NGF治疗临床研究显示出了前景。奥尔森等人表明，NGF治疗可增加大脑皮层的血流量、[11C]尼古丁摄取量以及11C结合量。此外，NGF输注可使脑电图模式正常化，并改善单词识别测试中的表现。对NGF或增强NGF的化合物进行进一步的临床试验，将有助于确定基于动物研究来设计临床相关药物的方法是否对AD治疗有利。拉尔斯·奥尔森（本卷）报告了关于NGF在AD患者中有效性的进一步研究结果。
